Skip to main content
SpringerLink
Log in

Weight Loss Medications in Adolescents

  • Chapter
  • First Online:
Insulin Resistance

Part of the book series: Contemporary Endocrinology ((COE))

  • 915 Accesses

Abstract

A strong association exists between weight gain and the development of metabolic diseases, including hypertension, diabetes, and coronary artery disease, as well as increased mortality rates. It is also clear that weight loss can markedly improve insulin resistance (IR) and other markers of adverse health risks in obese individuals. Currently available treatments include diet, exercise, medications, and surgery. Pharmacotherapy for obesity is a treatment approach that has intermediate effectiveness and risk between behavioral therapy and surgery and has been advocated as a “mainstream” treatment option that should be discussed with patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. JAMA. 2005;293(15):1861–7.

    Article  CAS  PubMed  Google Scholar 

  2. National Heart Lung, and Blood Institute (NHLBI) and North American Association for the Study of Obesity (NAASO). Practical guide on the identification, evaluation, and treatment of overweight and obesity in adults. Bethesda: National Institutes of Health; 2000. NIH Publication No. 00-4084. 2006. Ref Type: Generic.

    Google Scholar 

  3. Ajani UA, Lotufo PA, Gaziano JM, et al. Body mass index and mortality among US male physicians. Ann Epidemiol. 2004;14(10):731–9.

    Article  PubMed  Google Scholar 

  4. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab. 2004;89(6):2583–9.

    Article  CAS  PubMed  Google Scholar 

  5. Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. JAMA. 2003;289(2):187–93.

    Article  PubMed  Google Scholar 

  6. Folsom AR, Kushi LH, Anderson KE, et al. Associations of general and abdominal obesity with multiple health outcomes in older women: the Iowa Women’s Health Study. Arch Intern Med. 2000;160(14):2117–28.

    Article  CAS  PubMed  Google Scholar 

  7. McTigue KM, Harris R, Hemphill B, et al. Screening and interventions for obesity in adults: summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2003;139(11):933–49.

    Article  PubMed  Google Scholar 

  8. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142(7):532–46.

    Article  CAS  PubMed  Google Scholar 

  9. Maggard MA, Shugarman LR, Suttorp M, et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med. 2005;142(7):547–59.

    Article  PubMed  Google Scholar 

  10. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults – the evidence report. National Institutes of Health. Obes Res 1998;6 Suppl 2:51S–209S.

    Google Scholar 

  11. Snow V, Barry P, Fitterman N, Qaseem A, Weiss K. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2005;142(7):525–31.

    Article  PubMed  Google Scholar 

  12. Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord. 2002;26(2):262–73.

    Article  CAS  PubMed  Google Scholar 

  13. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295(13):1549–55.

    Article  CAS  PubMed  Google Scholar 

  14. Yanovski SZ. Pharmacotherapy for obesity – promise and uncertainty. N Engl J Med. 2005;353(20):2187–9.

    Article  CAS  PubMed  Google Scholar 

  15. Colman E. Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann Intern Med. 2005;143(5):380–5.

    Article  PubMed  Google Scholar 

  16. Bray GA. Drug treatment of obesity. Rev Endocr Metab Disord. 2001;2(4):403–18.

    Article  CAS  PubMed  Google Scholar 

  17. Weintraub M, Hasday JD, Mushlin AI, Lockwood DH. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch Intern Med. 1984;144(6):1143–8.

    Article  CAS  PubMed  Google Scholar 

  18. Stafford RS, Radley DC. National trends in antiobesity medication use. Arch Intern Med. 2003;163(9):1046–50.

    Article  PubMed  Google Scholar 

  19. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;335(9):609–16.

    Article  CAS  PubMed  Google Scholar 

  20. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med. 1998;339(11):719–24.

    Article  CAS  PubMed  Google Scholar 

  21. Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2004;110(18):2952–67.

    Article  PubMed  Google Scholar 

  22. Kushner RF, Blatner DJ. Risk assessment of the overweight and obese patient. J Am Diet Assoc. 2005;105(5 Suppl 1):S53–62.

    Article  PubMed  Google Scholar 

  23. Jackson JE, Doescher MP, Saver BG, Hart LG. Trends in professional advice to lose weight among obese adults, 1994 to 2000. J Gen Intern Med. 2005;20(9):814–8.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Foster GD, Wadden TA, Makris AP, et al. Primary care physicians’ attitudes about obesity and its treatment. Obes Res. 2003;11(10):1168–77.

    Article  PubMed  Google Scholar 

  25. Galuska DA, Will JC, Serdula MK, Ford ES. Are health care professionals advising obese patients to lose weight? JAMA. 1999;282(16):1576–8.

    Article  CAS  PubMed  Google Scholar 

  26. Puhl RM, Brownell KD. Confronting and coping with weight stigma: an investigation of overweight and obese adults. Obesity (Silver Spring). 2006;14(10):1802–15.

    Article  Google Scholar 

  27. Puhl RM, Brownell KD. Psychosocial origins of obesity stigma: toward changing a powerful and pervasive bias. Obes Rev. 2003;4(4):213–27.

    Article  CAS  PubMed  Google Scholar 

  28. Schwartz MB, Chambliss HO, Brownell KD, Blair SN, Billington C. Weight bias among health professionals specializing in obesity. Obes Res. 2003;11(9):1033–9.

    Article  PubMed  Google Scholar 

  29. Simkin-Silverman LR, Gleason KA, King WC, et al. Predictors of weight control advice in primary care practices: patient health and psychosocial characteristics. Prev Med. 2005;40(1):71–82.

    Article  PubMed  Google Scholar 

  30. Teachman BA, Brownell KD. Implicit anti-fat bias among health professionals: is anyone immune? Int J Obes Relat Metab Disord. 2001;25(10):1525–31.

    Article  CAS  PubMed  Google Scholar 

  31. Foster GD, Wadden TA, Phelan S, Sarwer DB, Sanderson RS. Obese patients’ perceptions of treatment outcomes and the factors that influence them. Arch Intern Med. 2001;161(17):2133–9.

    Article  CAS  PubMed  Google Scholar 

  32. Hamman RF, Wing RR, Edelstein SL, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006;29(9):2102–7.

    Article  PubMed  Google Scholar 

  33. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.

    Article  CAS  PubMed  Google Scholar 

  34. Lindstrom J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368(9548):1673–9.

    Article  PubMed  Google Scholar 

  35. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353(20):2111–20.

    Article  CAS  PubMed  Google Scholar 

  36. Frank A. The long-term management of obesity with continuing pharmacotherapy. Obes Res. 2004;12(11):1821–7.

    Article  PubMed  Google Scholar 

  37. O’Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. A systematic review of the clinical effectiveness of orlistat used for the management of obesity. Obes Rev. 2004;5(1):51–68.

    Article  PubMed  Google Scholar 

  38. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998;352(9123):167–72.

    Article  CAS  PubMed  Google Scholar 

  39. Hutton B, Fergusson D. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am J Clin Nutr. 2004;80(6):1461–8.

    Article  CAS  PubMed  Google Scholar 

  40. Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2002;25(6):1033–41.

    Article  CAS  PubMed  Google Scholar 

  41. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–61.

    Article  CAS  PubMed  Google Scholar 

  42. Ozkan B, Bereket A, Turan S, Keskin S. Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr. 2004;163(12):738–41.

    Article  PubMed  Google Scholar 

  43. Maahs D, de Serna DG, Kolotkin RL, et al. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract. 2006;12(1):18–28.

    Article  PubMed  Google Scholar 

  44. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA. 2005;293(23):2873–83.

    Article  CAS  PubMed  Google Scholar 

  45. Ryder JR, Kaizer A, Rudser KD, Gross A, Kelly AS, Fox CK. Effect of phentermine on weight reduction in a pediatric weight management clinic. Int J Obes (Lond). 2017;41(1):90–3.

    Article  CAS  Google Scholar 

  46. Fox CK, Kaizer AM, Rudser KD, et al. Meal replacements followed by topiramate for the treatment of adolescent severe obesity: a pilot randomized controlled trial. Obesity (Silver Spring). 2016;24(12):2553–61.

    Article  CAS  Google Scholar 

  47. Fox CK, Marlatt KL, Rudser KD, Kelly AS. Topiramate for weight reduction in adolescents with severe obesity. Clin Pediatr (Phila). 2015;54(1):19–24.

    Article  Google Scholar 

  48. Nathan BM, Rudser KD, Abuzzaha MJ, et al. Predictors of weight-loss response with glucagon-like peptide-1 receptor agonist treatment among adolescents with severe obesity. Clin Obes. 2016;6(1):73–8.

    Article  CAS  PubMed  Google Scholar 

  49. Tamborlane WV, Barrientos-Perez M, Fainberg U, et al. Liraglutide in children and adolescents with type 2 diabetes. N Engl J Med. 2019;381(7):637–46.

    Article  CAS  PubMed  Google Scholar 

  50. Srivastava G, Apovian CM. Current pharmacotherapy for obesity. Nat Rev Endocrinol. 2017;14(1):12–24.

    Article  PubMed  CAS  Google Scholar 

  51. Kuhnen P, Clement K, Weigand S, et al. Proopiomelanocortin deficiency-treated with a melanocortin-4 receptor agonist. N Engl M Med. 2016;375(3):240–6.

    Article  CAS  Google Scholar 

  52. Ness-Abramof R, Apovian CM. Drug-induced weight gain. Drugs Today (Barc). 2005;41(8):547–55.

    Article  CAS  Google Scholar 

  53. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686–96.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Swedish Medical Center, Denver Endocrinology/Diabetes & Thyroid Center PC, Englewood, CO, USA

    Linda L. Buckley

  2. Department of Medicine, University of Colorado Denver School of Medicine, Aurora, CO, USA

    Daniel H. Bessesen

  3. Section of Pediatric Endocrinology, University of Colorado School of Medicine, Children’s Hospital Colorado, Aurora, CO, USA

    Philip S. Zeitler

Authors
  1. Linda L. Buckley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel H. Bessesen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Philip S. Zeitler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philip S. Zeitler .

Editor information

Editors and Affiliations

  1. Section of Pediatric Endocrinology, Children’s Hospital Colorado, Aurora, CO, USA

    Philip S. Zeitler

  2. Department of Pediatrics, Children’s Hospital Colorado, Aurora, CO, USA

    Kristen J. Nadeau

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Buckley, L.L., Bessesen, D.H., Zeitler, P.S. (2020). Weight Loss Medications in Adolescents. In: Zeitler, P., Nadeau, K. (eds) Insulin Resistance. Contemporary Endocrinology. Humana, Cham. https://doi.org/10.1007/978-3-030-25057-7_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-25057-7_19

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-25055-3

  • Online ISBN: 978-3-030-25057-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation